Computer- and Structure-Based Lead Identification for Epigenetic Targets

Epigenetic Targets in Drug Discovery

Volumn 42, Issue , 2010, Pages 57-85

  Heinke, Ralf ^a   Uciechowska, Urszula ^a   Sippl, Wolfgang ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Computer based design; Epigenetic target structures; Ligand docking

Indexed keywords

EID: 85018193571     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527627073.ch3     Document Type: Chapter

References (106)

1. Wolffe, A.P. and Matzke, M.A. (1999) Epigenetics: regulation through repression. Science, 286, 481-486.
2. Kouzarides, T. (2007) Chromatin modifications and their function. Cell, 128, 693-705.
3. Finnin, M.S., Donigian, J.R., Cohen, A., Richon, V.M., Rifkind, R.A., Marks, P.A. et al. (1999) Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature, 401, 188-193.
4. Kirchmair, J., Distinto, S., Schuster, D., Spitzer, G., Langer, T. and Wolber, G. (2008) Enhancing drug discovery through in silico screening: strategies to increase true positives retrieval rates. Current Medicinal Chemistry, 15, 2040-2053.
5. Hawkins, P.C.D., Skillman, A.G. and Nicholls, A. (2007) Comparison of shape-matching and docking as virtual screening tools. Journal of Medicinal Chemistry, 50, 74-82.
6. Evers, A., Hessler, G., Matter, H. and Klabunde, T. (2005) Virtual screening of biogenic amine-binding G-protein coupled receptors: comparative evaluation of protein-and ligand-based virtual screening protocols. Journal ofMedicinal Chemistry, 48, 5448-5465.
7. Kirchmair, J., Laggner, C., Wolber, G. and Langer, T. (2005) Comparative analysis of protein-bound ligand conformations with respect to catalyst's conformational space subsampling algorithms. Journal of Chemical Information and Modeling, 45, 422-430.
8. Stahl, M., Guba, W. and Kansy, M. (2006) Integrating molecular design resources within modern drug discovery research: the Roche experience. Drug Discovery Today, 11, 326-333.
9. Wermuth, C.G., Ganellin, C.R., Lindberg, P. and Mitschler, L.A. (1998) Glossaryof terms used in medicinal chemistry (lUPAC Recommendations 1997). Annual ReportsinMedicinal Chemistry, 33,385-395.
10. Ahlstrom, M.M., Ridderstrom, M., Luthman, K. and Zamora, I. (2005) Virtual screening and scaffold hopping based on GRID molecular interaction fields. Journal of Chemical Information and Modeling, 45, 1313-1323.
11. Stahura, F.L. and Bajorath, J. (2005) New methodologies for ligand-based virtual screening. Current Pharmaceutical Design, 11, 1189-1192.
12. Cramer, R.D. III, Patterson, D.E. and Bunce, J.D. (1988) Comparative molecular field analysis (CoMFA) 1. Effect of shape on binding of steroids to carrier proteins. Journal of the American Chemical Society, 110, 5959-5967.
13. Klebe, G. and Abraham, U. (1993) On the prediction of binding properties of drug molecules by comparative molecular field analysis. Journal ofMedicinal Chemistry, 36, 70-80.
14. Baroni, M., Constantino, G., Cruciani, G., Riganelli, D., Valigli, R. and Clementi, S. (1993) Generating optimal linear pls estimations (GOLPE): An advanced chemometric tool for handling 3D-QSAR problems. Quantitative Structure-Activity Relationships, 12, 9-20.
15. Sippl, W. (2006) in Methods and Principles in Medicinal Chemistry-Pharmacophore Generation and Concepts (eds T. Langer and R. Hofmann) (series eds H. Kubinyi, G. Folkers and R. Mannhold), VCH Publisher, New York.
16. Cruciani, G. (ed.) (2006) Methods and Principles in Medicinal Chemistry-Molecular Interaction Fields (series eds H. Kubinyi, G. Folkers and R. Mannhold), VCH Publisher, New York.
17. Akamatsu, M. (2002) Current state and perspectives of 3D QSAR. Current Topics in Medicinal Chemistry, 2, 1381-1394.
18. Doweyko, A.M. (2004) 3D QSAR illusions. Journal ofComputer-Aided Molecular Design, 18, 587-596.
19. Osterberg, F., Morris, G.M., Sanner, M.F., Olson, A.J. and Goodsell, D.S. (2002) Automated docking to multiple target structures: incorporation of protein mobilityandstructuralwaterheterogeneity inAutoDock. Proteins, 46, 34-40.
20. Gold, Cambridge Crystallographic Data Centre, Cambridge, UK, http://www.ccdc.cam.ac.uk.
21. Glide, Schrödinger, Portland, OR, http://www.schroedinger.com.
22. FlexE, BiosolveIT, St. Augustin, Germany, http://www.biolsolveit.de.
23. Klebe, G. (2006) Virtual ligand screening. Drug Discovery Today, 11, 580-594.
24. Tame, J.R. (2005) Scoring functions-the first 100 years. Journal ofComputer-Aided Molecular Design, 17, 445-451.
25. Leach, A.R., Shoichet, B.K. and Peishoff, C.E. (2006) Prediction of protein-ligand interactions. Docking and scoring: successes and gaps. Journal ofMedicinal Chemistry, 49, 5852-5855.
26. Kitchen, D.B., Decornez, H., Furr, J.R. and Bajorth, J. (2004) Docking and scoring in virtual screening for drug discovery: Methods and applications. Nature Reviews. Drug Discovery, 3, 935-949.
27. Pearlman, D.A. (2005) Evaluating the molecular mechanics Poisson-Boltzmann surface area free energy method using a congeneric series of ligands to p38 MAP kinase. Journal of Medicinal Chemistry, 48, 7796-7807.
28. Chang, C.E. and Gilson, M.K. (2004) Free energy, entropy, and induced fit in host-guest recognition: calculations with the second-generation mining minima algorithm. Journal of the American Chemical Society, 126, 13156-13164.
29. Deng, Y. and Roux, B. (2006) Calculation of standard binding free energies: Aromatic molecules in the T4 lysozyme L99A mutant. Journal of Chemical Theory and Computation, 2, 1255-1273.
30. Siedlecki, P., Boy, R.G., Comagic, S., Schirrmacher, R., Wiessler, M., Zielenkiewicz, P., Suhai, S. and Lyko, F. (2003) Establishment and functional validation of a structural homology model for human DNA methyltransferase 1. Biochemical and Biophysical Research Communications, 306, 558-563.
31. Siedlecki, P., Boy, R.G., Musch, T., Brueckner, B., Suhai, S., Lyko, F. and Zielenkiewicz, P. (2006) Discovery oftwo novel, small-molecule inhibitors of DNA methylation. Journal ofMedicinal Chemistry, 49, 678-683.
32. Moustakas, D.T., Lang, P.T., Pegg, S., Pettersen, E., Kuntz, I.D. et al. (2006) Development and validation of a modular, extensible docking program: DOCK 5. Journal ofComputer-Aided Molecular Design, 20, 601-619.
33. de Ruijter, A.J., van Gennip, A.H., Caron, H.N., Kemp, S. and van Kuilenburg, A.B. (2003) Histone deacetylases (HDACs): characterization of the classical HDAC family. The Biochemical Journal, 370, 737-749.
34. Hodawadekar, S.C. and Marmorstein, R. (2007) Chemistry of acetyl transfer by histone modifying enzymes: structure, mechanism and implications for effector design. Oncogene, 26, 5528-5540.
35. Zhang, Y., Fang, H., Jiao, J. and Xu, W. (2008) The structure and function of histone deacetylases: The target for anticancer therapy. Current Medicinal Chemistry, 15, 2840-2849.
36. Massa, S., Mai, A., Sbardella, G., Esposito, M., Ragno, R., Loidl, P. et al. (2001) G. 3-(4-Aroyl-1 H-pyrrol-2-yl)-N-hydroxy-2-propenamides, a new class of synthetic histone deacetylase inhibitors. Journal of Medicinal Chemistry, 44, 2069-2072.
37. Van Ommeslaeghe, K., Elaut, G., Brecx, V., Papeleu, P., Iterbeke, K., Geerlings, P. et al. (2003) Amide analogues of TSA: Synthesis, binding mode analysis and HDAC inhibition. Bioorganic & Medicinal Chemistry Letters, 13, 1861-1864.
38. Wang, D.F., Wiest, O., Helquist, P., Lan-Hargest, H.Y. and Wiech, N.L. (2004) On the function ofthe 14 A long internal cavity of histone deacetylase-like protein: implications for the design of histone deacetylase inhibitors. Journal of Medicinal Chemistry, 47, 3409-3417.
39. Lu, Q., Wang, D.S., Chen, C.S., Hu, Y.D. and Chen, C.S. (2005) Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. Journal of Medicinal Chemistry, 48, 5530-5535.
40. Rodriquez, M., Terracciano, S., Cini, E., Settembrini, G., Bruno, I., Bifulco, G. et al. (2006) Total synthesis, NMR solution structure, and binding model of the potent histone deacetylase inhibitor FR235222. Angewandte Chemie-International Edition, 45, 423-427.
41. Maulucci, N., Chini, M.G., Di Micco, S., Izzo, I., Cafaro, E., Russo, A. et al. (2007) Molecular insights into azumamide E histone deacetylases inhibitory activity. Journal ofthe American Chemical Society, 129, 3007-3012.
42. Liu, T., Kapustin, G. and Etzkorn, F.A. (2007) Design and synthesis of a potent histone deacetylase inhibitor. Journal of Medicinal Chemistry, 50, 2003-2006.
43. Micco, D.S., Terracciano, S., Bruno, I., Rodriquez, M., Riccio, R., Taddei, M. et al. (2008) Molecular modeling studies toward the structural optimization of new cyclopeptide-based HDAC inhibitors modeled on the natural product FR235222. Bioorganic and Medicinal Chemistry, 16, 8635-8642.
44. Chen, P.C., Patil, V., Guerrant, W., Green, P. and Oyelere, A.K. (2008) Synthesis and structure-activity relationship of histone deacetylase (HDAC) inhibitors with triazole-linked cap group. Bioorganic and Medicinal Chemistry, 16, 4839-4853.
45. Lavoie, R., Bouchain, G., Frechette, S., Woo, S.H., Khalil, E.A., Leit, S. et al. (2001) Design and synthesis of a novel class of histone deacetylase inhibitors. Bioorganic & Medicinal Chemistry Letters, 11, 2847-2850.
46. Remiszewski, S.W., Sambucetti, L.C., Atadja, P., Bair, K.W., Cornell, W.D., Green, M.A. et al. (2002) Inhibitors of human histone deacetylase: Synthesis and enzyme and cellular activity of straight chain hydroxamates. Journal of Medicinal Chemistry, 45, 753-757.
47. Mai, A., Massa, S., Ragno, R., Cerbara, I., Jesacher, F., Loidl, P. and Brosch, G. (2003) 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-alkylamides as a new class ofsynthetic histone deacetylase inhibitors. 1. Design, synthesis, biological evaluation, and binding mode studies performed through three different docking procedures. Journal of Medicinal Chemistry, 46, 512-524.
48. Park, H. and Lee, S. (2004) Homology modeling, force field design, and free energy simulation studies to optimize the activities of histone deacetylase inhibitors. Journal of Computer-Aided Molecular Design, 16, 375-388.
49. Wang, D.-F., Helquist, P., Wiech, N.L. and Wiest, O. (2005) Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases. Journal of Medicinal Chemistry, 48, 6936-6947.
50. Kim, H.M., Hong, S.H., Kim, M.S., Lee, C.W., Kang, J.S., Lee, K. et al. (2007) Modification of cap group in d-lactam-based histone deacetylase (HDAC) inhibitors. Bioorganic & Medicinal Chemistry Letters, 17, 6234-6237.
51. Witter, D.J., Harrington, P., Wilson, K.J., Chenard, M., Fleming, J.C., Haines, H. et al. (2008) Optimization of biaryl selective HDAC1&2 inhibitors. Bioorganic & Medicinal Chemistry Letters, 18, 726-731.
52. Moradei, O.M., Mallais, T.C., Frechette, S., Paquin, I., Tessier, P.E., Leit, S.M. et al. (2007) Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. Journal of Medicinal Chemistry, 50, 5543-5546.
53. Schäfer, S., Saunders, L., Eliseeva, E.A. Jung, M., Schwienhorst, A., Dickmanns, A. et al. (2008) Phenylalanine-containing hydroxamic acids as selective inhibitors of class IIb histone deacetylases (HDACs). Bioorganic and Medicinal Chemistry, 16, 2011-2033.
54. Yan, C., Xiu, Z., Li, X., Li, S., Hao, C. and Teng, H. (2008) Comparative molecular dynamics simulations of histone deacetylase-like protein: Binding modes and free energy analysis to hydroxamic acid inhibitors. Proteins, 73, 134-149.
55. Mukherjee, P., Pradhan, A., Shah, F., Tekwanib, B.L. and Averya, M.A. (2008) Structural insights into the Plasmodium falciparum histone deacetylase 1 (PfHDAC-1): A novel target for the development of antimalarial therapy. Bioorganic and Medicinal Chemistry, 16, 5254-5265.
56. Weerasinghe, S.V.W., Estiu, G., Wiest, O. and Pflum, M.K.H. (2008) Residues in the 11 Å channel of histone deacetylase 1 promote catalytic activity: implications for designing isoform-selective histone deacetylase inhibitors. Journal of Medicinal Chemistry, 51, 5542-5551.
57. Estiu, G., Greenberg, E., Harrison, C.B., Kwiatkowski, N.P., Mazitschek, R., Bradner, J.E. et al. (2008) Structural origin of selectivity in class Il-selective histone deacetylase inhibitors. Journal of Medicinal Chemistry, 51, 2898-2906.
58. Schäfer, S., Saunders, L., Schlimme, S., Valkov, V., Wagner, J., Kratz, F. et al. (2009) Pyridylalanine-containing hydroxamic acids as selective HDAC6 inhibitors. ChemMedChem, 4, 283-290.
59. Wang, D.F., Wiest, O., Helquist, P., Lan-Hargest, H.Y. and Wiech, N.L. (2004) QSAR studies of PC-3 cell line inhibition activity of TSA and SAHA-like hydroxamic acids. Bioorganic & Medicinal Chemistry Letters, 14, 707-711.
60. Xie, A., Liao, C., Li, Z., Ning, Z., Hu, W., Lu, X., Shi, L. and Zhou, J. (2004) Quantitative structure-activity relationship study of histone deacetylase inhibitors. Current Medicinal Chemistry Anticancer Agents, 4, 273-299.
61. Eikel, D., Lampen, A. and Nau, H. (2006) Teratogenic effects mediated by inhibition of histone deacetylases: evidence from quantitative structure activity relationships of 20 valproic acid derivatives. Chemical Research in Toxicology, 19, 272-278.
62. Guo, Y., Xiao, J., Guo, Z., Chu, F., Cheng, Y. and Wu, S. (2005) Exploration of a binding mode of indole amide analogues as potent histone deacetylase inhibitors and 3D-QSAR analyses. Bioorganic and Medicinal Chemistry, 13, 5424-5434.
63. Juvale, D.C., Kulkarni, V.V., Deokar, H.S., Wagh, N.K., Padhye, S.B. and Kulkarni, V.M. (2006) 3D-QSAR of histone deacetylase inhibitors: hydroxamate analogues. Organic and Biomolecular Chemistry, 4, 2858-2868.
64. Ragno, R., Simeoni, S., Valente, S., Massa, S. and Mai, A. (2006) 3-D QSAR studies on histone deacetylase inhibitors. A GOLPE/GRID approach on different series ofcompounds. Journal of Chemical Information andModeling, 46,1420-1430.
65. Ragno, R., Simeoni, S., Rotili, D., Caroli, A., Botta, G., Brosch, G., Massa, S. and Mai, A. (2008) Class II-selective histone deacetylase inhibitors. Part 2: alignment-independent GRIND 3-D QSAR, homology and docking studies. European Journal ofMedicinal Chemistry, 43, 621-632.
66. Price, S., Bordogna, W., Bull, R.J., Clark, D.E., Crackett, P.H., Dyke, H.J. et al. (2007) Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors. Bioorganic & Medicinal Chemistry Letters, 17, 370-375.
67. Vadivelan, S., Sinha, B.N., Rambabu, G., Boppana, K. and Jagarlapudi, S. (2008) Pharmacophore modeling and virtual screening studies to design some potential histone deacetylase inhibitors as new leads. Journal ofMolecular Graphics & Modelling, 26, 935-946.
68. Chen, Y., Jiang, Y.J., Zhou, J.W., Yu, Q.S. and You, Q.D. (2008) Identification of ligand features essential for HDACs inhibitors by pharmacophore modeling. Journal ofMolecular Graphics & Modelling, 25, 1160-1168.
69. Schuetz, A., Min, J., Antoshenko, T., Wang, C.L., Allali-Hassani, A., Dong, A. et al. (2007) Structural basis of inhibition of the human NAD +-dependent deacetylase SIRT5 by suramin. Structure (London, England: 1993), 15, 377-389.
70. Sanders, B.D., Zhao, K., Slama, J.T. and Marmorstein, R. (2007) Structural basis for nicotinamide inhibition and base exchange in Sir2 enzymes. Molecular Cell, 25, 463-472.
71. Trapp, J., Meier, R., Hongwiset, D., Kassack, M.U., Sippl, W. and Jung, M. (2007) Structure-activity studies on suramin analogues as inhibitors of NAD( + )-dependent histone deacetylases (sirtuins). ChemMedChem, 2, 1419-1431.
72. Neugebauer, R.C., Sippl, W. and Jung, M. (2008) Inhibitors of NAD + dependent histone deacetylases (sirtuins). Current Pharmaceutical Design, 14, 562-573.
73. Trapp, J., Jochum, A., Meier, R., Saunders, L., Marshall, B., Kunick, C. et al. (2006) Adenosine mimetics as inhibitors ofNAD (+ )-dependent histone deacetylases, from kinase to sirtuin inhibition. Journal of Medicinal Chemistry, 49, 7307-7316.
74. Tervo, A.J., Kyrylenko, S., Niskanen, P., Salminen, A., Leppanen, J., Nyronnen, T.H. et al. (2004) An in silico approach to discovering novel inhibitors of human sirtuin type 2. Journal of Medicinal Chemistry, 47, 6292-6298.
75. UNITY, Tripos Assoc., St. Louis, USA.
76. Crivori, P., Cruciani, G., Carrupt, P.A. and Testa, B. (2000) Predicting blood-brain barrier permeation from threedimensional molecular structure. Journal of Medicinal Chemistry, 43, 2204-2216.
77. Tervo, A.J., Suuronen, T., Kyrylenko, S., Kuusisto, E., Kiviranta, P.H., Salminnen, A. et al. (2006) Discovering inhibitors of human sirtuin type 2: novel structural scaffolds. Journal ofMedicinal Chemistry, 49, 7239-7241.
78. Kiviranta, P.H., Leppanen, J., Kyrylenko, S., Salo, H.S., Lahtela-Kakkonen, M., Tervo, A.J. et al. (2006) N, N0-bisbenzylidenebenzene-1,4-diamines and N,N0-bisbenzylidenenaphthalene-1,4-diamines as sirtuin type 2 (SIRT2) inhibitors. Journal ofMedicinal Chemistry, 49, 7907-7911.
79. Huhtiniemi, T., Suuronen, T., Rinne, V.M., Wittekindt, C., Lahtela-Kakkonen, M., Jarho, E. et al. (2008) Oxadiazole-carbonylaminothioureas as SIRT1 and SIRT2 inhibitors. Journal of Medicinal Chemistry, 51, 4377-4380.
80. Outeiro, T.F., Kontopoulos, E., Altmann, S.M., Kufareva, I., Strathearn, K.E., Amore, A.M. et al. (2007) Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models ofParkinson's disease. Science, 317, 516-519.
81. Abagyan, R., Totrov, M. and Kuznetsov, D. (1994) ICM-anew methodfor modeling and design: applications to docking and structure prediction. Journal of Computational Chemistry, 15, 488-498.
82. Neugebauer, R.C., Uchiechowska, U., Meier, R., Hruby, H., Valkov, V., Verdin, E. et al. (2008) Stucture activity studies on splitomicin derivatives as sirtuin inhibitors and computational prediction of binding mode. Journal ofMedicinal Chemistry, 51, 1203-1213.
83. Napper, A.D., Hixon, J., McDonagh, T., Keavey, K., Pons, J.F., Barker, J. et al. (2005) Discoveryofindoles as potentand selective inhibitors ofthe deacetylaseSIRT1. Journal of Medicinal Chemistry, 48, 8045-8054.
84. Posakony, J., Hirao, M., Stevens, S., Simon, J.A. and Bedalov, A. (2004) Inhibitors of Sir2: evaluation of splitomicin analogues. Journal of Medicinal Chemistry, 47, 2635-2644.
85. Heltweg, B., Gatbonton, T., Schuler, A.D., Posakony, J., Li, H., Goehle, S. et al. (2006) Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Research, 66, 4368-4377.
86. Wang, J., Wolf, R.M., Caldwell, J.W., Kollman, P.A. and Case, D.A. (2004) Development and testing of a general amber force field. Journal of Computational Chemistry, 25, 1157-1174.
87. Howitz, K.T., Bitterman, K.J., Cohen, H.Y., Lamming, D.W., Lavu, S., Wood, J.G. et al. (2003) Small molecule activators ofsirtuin expan Saccharomyces cerevisiae lifespan. Nature, 425, 191-196.
88. Huhtiniemi, T., Wittekindt, C., Laitinen, T., Leppanen, J., Salminen, A., Poso, A. et al. (2006) Comparative and pharmacophore model for deacetylase SIRT1. Journal of Computer-Aided Molecular Design, 20, 589-599.
89. Lin, Y., Fletcher, C.M., Zhou, J., Allis, C.D. and Wagner, G. (1999) Solution structure of the catalytic domain of GCN5 histone acetyltransferase bound to coenzyme A. Nature, 400, 86-89.
90. Trievel, R.C., Rojas, J.R., Sterner, D.E., Venkataramani, R.N., Wang, L., Zhou, J., Allis, C.D., Berger, S.L. and Marmorstein, R. (1999) Crystal structure and mechanism of histone acetylation of the yeast GCN5 transcriptional coactivator. Proceedings of the National Academy of Sciences ofthe United States ofAmerica, 96, 8931-8936.
91. Liu, X., Wang, L., Zhao, K., Thompson, P.R., Hwang, Y., Marmorstein, R. and Cole, P.A. (2008) The structural basis of protein acetylation by the p300/CBP transcriptional coactivator. Nature, 451, 846-850.
92. Bhaumik, S.R., Smith, E. and Shilatifard, A. (2007) Covalent modifications of histones during development and disease pathogenesis. Nature Structural & Molecular Biology, 14, 1008-1016.
93. Zhang, X., Zhou, L. and Cheng, X. (2000) Crystal structure of the conserved core of protein arginine methyltransferase PRMT3. The EMBO Journal, 19, 3509-3519.
94. Zhang, X. and Cheng, X. (2003) Structure of the predominant protein arginine methyltransferase PRMT1 and analysis of its binding to substrate peptides. Structure (Camb), 11, 509-520.
95. Ragno, R., Simeoni, S., Castellano, S., Vicidomini, C., Mai, A., Caroli, A. et al. (2007) Small molecule inhibitors of histone arginine methyltransferases: homology modeling, molecular docking, binding mode analysis, and biological evaluations. Journal of Medicinal Chemistry, 50, 1241-1253.
96. Mai, A., Valente, S., Cheng, D., Perrone, A., Ragno, R., Simeoni, S. et al. (2007) Synthesis and biological validation of novel synthetic histone/protein methyltransferase inhibitors. ChemMedChem, 3, 987-991.
97. Spannhoff, A., Heinke, R., Bauer, I., Trojer, P., Metzger, E., Gust, R. et al. (2007) Target-based approach to inhibitors of histone arginine methyltransferases. Journal of Medicinal Chemistry, 50, 2319-2325.
98. Heinke, R., Spannhoff, A., Huda, E., Meier, R., Jung, M. and Sippl, W. (2009) Virtual screening and biological characterization of histone methyltransferase inhibitors PRMT1. ChemMedChem, 4, 69-77.
99. Spannhoff, A., Machmur, R., Heinke, R., Trojer, P., Bauer, I., Brosch, G. et al. (2007) A novel arginine methyltransferase inhibitor with cellular activity. Bioorganic & Medicinal Chemistry Letters, 17, 4150-4153.
100. Cheng, D., Yadav, N., King, R.W., Swanson, M.S., Weinstein, E.J. and Bedford, M.T. (2004) Small molecule regulators of protein arginine methyltransferases. The Journal of Biological Chemistry, 279, 23892-23899.
101. Mason, J.S., Morize, I., Menard, P.R., Cheney, D.L., Hulme, C. and Labaudiniere, R.F. (1999) New 4-point pharmacophore method for molecular similarity and diversity applications: overview of the method and applications, including a novel approach to the design of combinatorial libraries containing privileged substructures. Journal of Medicinal Chemistry, 42, 3251-3264.
102. Zhang, X., Yang, Z., Khan, S.I., Horton, J.R., Tamaru, H., Selker, E.U. et al. (2003) Structural basis for the product specificity ofhistone lysine methyltransferases. Molecular Cell, 12, 177-185.
103. Shi, Y.J., Lan, F., Matson, C., Mulligan, P., Whetstine, J.R., Cole, P.A. et al. (2004) Histone demethylation mediated by the nuclear arnine oxidase homologue LSD1. Cell, 119, 941-953.
104. Tsukada, Y., Fang, J., Erdjument-Bromage, H., Warren, M.E., Borchers, C.H., Tempst, P. et al. (2006) Histone demethylation by a family of JmjC domain-containing proteins. Nature, 439, 811-816.
105. Wang, G.G., Allis, C.D. and Chi, P. (2007) Chromatin remodeling and cancer, Part I: Covalent histone modifications. Trends in Molecular Medicine, 13, 363-372.
106. Rose, N.R., Ng, S.S., Mecinovi, ć J., Liénard, B.M., Bello, S.H., Sun, Z. et al. (2008) Inhibitor scaffolds for 2-oxoglutarate-dependent histone lysine demethylases. Journal of Medicinal Chemistry, 51, 7053-7055.